Evidence map›Paper›PMID 34336267›Full record

ArticleInternational journal of hypertension2021

Effects of Simplified Antihypertensive Treatment Algorithm on Hypertension Management and Hypertension-Related Death in Resource-Constricted Primary Care Setting between 1997 and 2017.

Mulalibieke Heizhati, Nanfang Li, Qiaoyan Shi, Xiaoguang Yao, Delian Zhang, Keming Zhou, Menghui Wang, Junli Hu, Gulinuer Duiyimuhan, Wen Jiang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hypertension, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mulalibieke HeizhatiNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.
Nanfang LiNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.ORCID https://orcid.org/0000-0003-1505-8566
Qiaoyan ShiNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.
Xiaoguang YaoNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.
Delian ZhangNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.
Keming ZhouNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.
Menghui WangNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.
Junli HuNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.
Gulinuer DuiyimuhanNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.
Wen JiangNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.
Jing HongNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.
Le SunNational Health Committee Key Laboratory of Hypertension Clinical Research, Hypertension Institute of Xinjiang, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region China, No. 91, Tianchi Road, Tianshan District, Urumqi 830001, Xinjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension management is poor in primary care settings of developing countries, where 75% of hypertensives are living. Exploring better ways to improve hypertension management and to decrease stroke and CVD death is needed such as introducing treatment algorithm. Therefore, we selected intervention counties from Xinjiang, an underdeveloped region in China, and introduced antihypertensive treatment algorithm, comprising locally available and affordable agents, to primary health providers since 1998. Program effects were evaluated using the data collected in various ways including cross-sectional screenings to population ≥30 years between 1998 and 2015 by comparing treatment and control rates of hypertension, changes in blood pressure (BP) levels and distribution, and proportion of case/total and NCD death for CVD and stroke. Compared to 1998-2000, treatment rate was improved by 2.78 fold (11.2% vs. 32.1%,

Identifiers

PMID34336267
PMCPMC8294957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.